GTx said enobosarm, its experimental drug for cancer-induced muscle wasting, failed to enhance body mass and physical function in cancer patients in two late-stage trials. The firm plans to meet with the FDA to discuss the future of the drug, which received fast-track designation this year. In one of the studies, patients gained lean body mass.

Full Story:

Related Summaries